Treatment Trials

7 Clinical Trials for Various Conditions

Focus your search

COMPLETED
Dermal Irritation, Sensitization and Cumulative Irritation Potential of 6% Bemotrizinol
Description

The purpose of this clinical trial is to evaluate the dermal safety of Bemotrizinol (6%).

Conditions
COMPLETED
14-Day Cumulative Irritation Patch Test in Subjects With Normal Skin - Chameleon
Description

to determine the ability of the test article to cause irritation to the skin of humans under controlled patch test conditions

COMPLETED
Evaluation of Experimental and Commercial Air-Activated, Adhesive Backed Heat Patches
Description

To assess the safety and tolerability for the extended wear of an experimental air-activated self adhesive patch.

COMPLETED
Evaluation of Experimental Heat Patch
Description

A disposable, air-activated, adhesive backed heat patch is being developed to provide temporary relief from minor muscular ache and joint pains associated with overexertion strains and sprains as well as minor pain associated with arthritis. The aim of the study is to determine the safety and tolerability of the patch during normal wear conditions.

TERMINATED
A Comparative Study to Evaluate Two Air-Activated Adhesive Backed Heat Patches
Description

A disposable, air-activated, adhesive backed heat patch is being evaluated. Study terminated -O subjects.

Conditions
COMPLETED
Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion
Description

The purpose of the study is to determine the irritation potential of repeat applications of abametapir lotion on normal skin.

Conditions
COMPLETED
A Study to Evaluate the Irritation Potential of GSK2894512 Cream on Skin in Healthy Subjects
Description

This study is conducted to assess the potential of topically-applied GSK2894512 cream at 3 concentrations (0.5%, 1%, and 2%) to induce skin irritation at the site of application in healthy subjects. Results from this study will be considered when selecting the concentration(s) of GSK2894512 to evaluate in the Phase II and Phase III clinical safety and efficacy studies. Approximately 40 subjects will be enrolled in order to have at least 30 evaluable subjects complete the study. The total duration of subject participation may be up to 50 days.

Conditions